Introduction
Epilepsy is a multifactorial condition whose pathogenesis is influenced by both genetic and acquired factors [1] [2] [3] . Among genetic factors, mutations in the neuronal voltage-gated sodium channel gene (SCN1A) have been associated with epilepsy [4] .
SCN1A (chromosomal location 2q24.3) encompasses 26 exons and belongs to a family of genes coding for neuronal voltage-gated sodium channels, which are responsible for sodium ion transport in the cell and thus for neuronal transmitting. SCN1A encodes the alpha subunit of the sodium channel NaV1.1, which mediates the initiation and propagation of neuronal action potentials. In SCN1A knockout mice, there was a significant decline in the sodium current in the hippocampal interneurons that are critical for gamma-aminobutyric acid (GABA) À mediated neuronal inhibition [4] . A missense mutation in SCN1A leads to dysfunction of inhibitory GABAergic neurons, resulting in brain hyperexcitability and seizures in infants [5] . Mutations in the SCN1A gene lead to severe forms of epilepsy such as Dravet syndrome, or milder forms such as generalized epilepsy with febrile seizures plus (GEFS+), simple febrile seizures and also a non-epileptic condition, familial hemiplegic migraine [6] .
Apart from their role in epileptogenesis, the voltage-gated sodium channels also play a major role as antiepileptic drug (AED) targets [6, 7] . SCN1A is a target of several AEDs, with some studies demonstrating an association between the SCN1A c.3184A > G/p. Thr1067Ala polymorphism and drug resistance [6, 7] . SCN1A c.3184A > G/p.Thr1067Ala is a missense polymorphism that results in p.Thr1067Ala substitution, which may affect the structurefunction relationship of the channel, leading to misfiring of brain neurons, thereby explaining its association with epilepsy [6] . The altered structure and functional properties of this ion channel may also influence the treatment for epilepsy [8] . The c.3184A > G/p. Thr1067Ala polymorphism has been suggested to be involved in the gating of sodium channels, thus rendering them insensitive to the blocking effect of different antiepileptic drugs [6, 8] . The association of the c.3184A > G/p.Thr1067Ala polymorphism with the risk of epilepsy was evaluated in several non-Caucasian populations [9, 10, 11, 12] and in a limited number of Caucasian populations [13] , but results were inconsistent, thus warranting additional studies.
The goal of antiepileptic drug treatment is the total control of seizures with minimal or no adverse effects to maintain an optimal quality of life [14] . Seizure remission is achieved in 2/3 of epilepsy patients, enabling children and adolescents to attend school and all other activities like their healthy peers [1, 2] . However, despite the current availability of numerous AEDs, 20-30% of patients have drug-resistant epilepsy [14, 15] .
The aim of this study was to investigate whether the SCN1A c.3184A > G/p.Thr1067Ala polymorphism is associated with a risk of epilepsy and the responsiveness to AEDs in children and adolescents with epilepsy in the Slovenian population.
Methods

Patients and controls
A total of 216 Slovenian children and adolescents with epilepsy, all of Central European Caucasian origin, were consecutively prospectively recruited during their regular outpatient follow-up visits between January 2011 and December 2014. Most children with drug-resistant epilepsy are followed up at the Department of Child, Adolescent and Developmental Neurology, University Children 0 s Hospital Ljubljana, which is the only tertiary neuropaediatric and epilepsy centre in Slovenia.
All patients included in this study were receiving antiepileptic treatment as either mono or polytherapy. The choice of AEDs was made according to the type of seizures and epilepsy syndromes. The medical data of all patients were collected retrospectively from electronic or paper hospital records. In particular we documented a family history of epilepsy, perinatal and neonatal complications, early development, the age at seizure onset, the seizure type, the aetiology of epilepsy, AED as mono or polytherapy and the responsiveness of seizures to drug treatment. The aetiology of epilepsy was reclassified according to ILAE 2017 criteria at the time of data analysis [16] .
The patients were divided into two groups: the inclusion criterion for the first group (patients in remission) was seizure remission, defined as a continuous period of !12 months of seizure freedom before inclusion. The second group, without remission, consisted of patients with uncontrolled seizures over the previous year, despite treatment with two or more appropriate AEDs, according to the ILAE criteria [15] . A period of one year was chosen to ensure adequate time for appropriate drug/dose adjustment to achieve seizure remission, or not. A titration period of two months was taken into account.
The exclusion criteria included poor compliance with AEDs, unreliable seizure frequency records, a history of pseudoseizures or the presence of any other condition that may itself aggravate epilepsy, such as malignant, hepatic, or chronic renal disease. Patients with progressive neurological disorders (progressive myoclonic epilepsies), Dravet syndrome or GEFS+ with SCN1A mutations were also excluded. The control group consisted of 95 healthy Slovenian blood donors, all under 30 years of age at the time of blood sampling. Only individuals without any nervous system disease or family history of epilepsy were eligible for inclusion in the control group. The Slovenian National Medical Ethics Committee approved the study and written informed consent was obtained from all participants and their parents or legal guardians before inclusion in the study.
DNA isolation and genotyping
We collected blood samples (3 ml) from 146 patients during their regular outpatient visits. DNA was isolated using the FlexiGene DNA Kit (Qiagen, Hilden, Germany). Buccal swabs were obtained from 70 patients who did not require venipuncture at the time of the follow-up visit. The DNA Mini Kit (QIAGEN) was used for DNA extraction from buccal swabs according to the recommended protocol. DNA from healthy controls was also isolated from venous blood using the FlexiGene DNA Kit (Qiagen). All DNA samples were stored at the hospital's biobank.
SCN1A c.3184A > G/p.Thr1067Ala (rs2298771) was genotyped using a fluorescence-based competitive allele-specific (KASPar) assay (KBiosciences, Herts, UK). Genotyping was carried out according to the touchdown protocol recommended by the manufacturer, with a hot-start activation of Taq DNA polymerase at 94 C for 15 min, followed by 10 touchdown cycles at 94 C for 20 s and annealing at 61 C for 60 s (the annealing temperature decreasing by 0.6 C per cycle to achieve a final temperature of 55 C) and finished with 26 amplification cycles at 94 C for 20 s and annealing at 55 C for 60 s. Allele discrimination was performed by reading the fluorescence at 30 C for 60 s. Genotyping was repeated in 20% of samples to check for genotyping accuracy.
Statistical analysis
Data were presented as the median and interquartile range (25%-75%) for continuous variables, and as frequencies for categorical variables. The Mann-Whitney test and the Fisher exact test were used to compare the distribution of continuous and categorical variables, respectively. The Chi-square test was used to assess deviation from Hardy-Weinberg equilibrium. To determine the association of genotypes with binary outcomes, univariable and multivariable logistic regression was used, calculating odds ratios (ORs) and 95% confidence intervals (CIs). P values less than 0.050 were considered statistically significant. All statistical analyses were carried out by IBM SPSS Statistics, version 19.0 (IBM Corporation, Armonk, NY, USA).
Results
The study population consisted of 216 children and adolescents with epilepsy, of whom 91 (42.4%) were males. Of the 95 healthy controls, 46 (48.9%) were males, and the median age was 21 (20) (21) (22) (23) years.
The median age at first seizure was 2.56 (0.65-5.60) years, and the diagnosis of epilepsy was made at a median age of 2.89 (0.77-6.13).
According to the aetiology, genetic epilepsy was determined in 75 (34.7%) of cases, structural in 81 patients (37.5%), genetic and structural/metabolic in 46 (21.3%) patients, while 14 (6.5%) patients had epilepsy of unknown aetiology. With reference to seizure type, a prevalence of generalized, focal and combined focal and generalized seizures was found in 84 (38.9%), 117 (54.2%) and 15 (6.9%) patients, respectively.
The first AED used as monotherapy was valproate in 88 (40.7%) patients, carbamazepine or oxcarbazepine in 81 (37.5%) patients, followed by levetiracetam, lamotrigine, ethosuximide and clobazam in 22 (10.2%), 14 (6.5%), 7 (3.2%) and 4 (1.9%) of cases, respectively.
At follow-up, 114 (52.8%) had achieved remission, while 102 patients (47.2%) were not in remission. Girls were less likely to achieve remission; of 125 female patients, 59 (47.2%) achieved remission compared to 55 (60.4%) of 91 male patients (OR = 0.59, 95% CI = 0.34-1.01, P = 0.055), although the association did not reach statistical significance.
Patients in remission tended to be older at the first seizure compared to the drug-resistant group (OR = 1.06, 95% CI = 0.99-1.14, P = 0.099). The age at diagnosis of patients with drug-resistant epilepsy was 2.5 years (0.4-4.6), while the age at the first seizure was 2.1 years (0.4-4.4). For patients in remission, the age at diagnosis was 3.1 years (1.1-7.2), and the age of the first seizure was 2.9 years (0.9-6.6).
Genotype frequencies
The frequency distribution of SCN1A genotypes in controls and epilepsy patients is shown in Table 1 . The SCN1A c.3184A > G/p. Thr1067Ala AA genotype was more frequent among epilepsy patients (44.0%; p-value for Hardy-Weinberg equilibrium, P HWE 0.608; minor allele frequency, MAF 0.331) compared to controls (33.7%; P HWE 0.495; MAF 0.435), while the frequency of heterozygosity was similar in the two groups (45.8% compared to 45.7%, respectively). The prevalence of homozygosity for the polymorphic G allele was lower among epilepsy patients compared to controls (10.2% and 20.7%, respectively).
Carriers of at least one polymorphic SCN1A c.3184A > G/p. Thr1067Ala G allele tended to have a lower risk of epilepsy (OR = 0.654, 95% CI = 0.39-1.08, P = 0.094), even when adjusted for gender (OR adj = 0.62, 95% CI = 0.37-1.04, P adj = 0.069). Compared to carriers of two normal alleles (AA), carriers of two polymorphic alleles (GG) had a significantly lower risk of epilepsy (OR = 0.38, 95% CI = 0.18-0.79, P = 0.010) and this association also remained significant after adjustment for gender (OR adj = 0.36, 95% CI = 0.17-0.76, P adj = 0.007) ( Table 1) .
Carriers of at least one polymorphic SCN1A c.3184A > G/p. Thr1067Ala G allele were significantly more likely to achieve remission than non-carriers (OR = 2.00, 95% CI = 1.16-3.46, P = 0.013). The same trend was observed after adjustment for gender and age at first seizure (OR adj = 1.78, 95% CI = 0.99-3.21, P adj = 0.056, Table 2 ).
Discussion
To our knowledge, this is the first study investigating the association of the SCN1A c.3184A > G/p.Thr1067Ala polymorphism with the risk of epilepsy and responsiveness to AEDs among Slovenian epilepsy patients.
We found that carriers of the polymorphic SCN1A allele G have a lower risk of epilepsy, especially in the homozygous state. Results in the literature differ between populations. SCN1A c.3184A > G/p. Thr1067Ala was associated with an overall susceptibility to epilepsy in the North Indian population as the AG genotype frequency was significantly higher in epilepsy patients compared to healthy controls [9] . Similar findings have been published for the Iranian population, where an association of the c.3184A > G/p. Thr1067Ala polymorphic allele with familial epileptic susceptibility was reported [10] . However, the number of participants in both studies was small. A study performed in Taiwan that included only patients with febrile convulsions did not report any association between SCN1A polymorphisms and this phenotype [11] . However, the study by Baum et al. [12] does show a correlation between epilepsy and SCN1A polymorphisms in a large cohort of patients from Malaysia, India and China, and additionally, it found a protective effect of the G allele on epilepsy risk, which emerged from a meta-analysis of their reports.
Our study showed that carriers of at least one polymorphic SCN1A c.3184A > G/p.Thr1067Ala G allele were significantly more likely to achieve remission. Multivariable analysis, adjusted for clinical factors (gender and age at the first seizure), demonstrated the same trend towards an association between SCN1A c.3184A > G/p.Thr1067Ala and remission, although it did not reach statistical significance. Our data suggest that this allele may have a protective role and that it may be associated with treatment efficacy. This is in agreement with other reports on the role of the c.3184A > G/p.Thr1067Ala polymorphism in treatment efficacy, suggesting that the resulting amino acid substitution may affect the structure and function of SCN1A, which is targeted by carbamazepine, phenytoin and other AEDs [17] . This polymorphism may thus lead to variations in the efficacy of epilepsy treatment among carriers of different genotypes. Our finding is in agreement with the findings in Chinese epileptic patients with focal seizures that c.3184A > G/p.Thr1067Ala was significantly associated with the efficacy of carbamazepine given as monotherapy [8] . In contrast, a recent study in Egyptian epileptic children claimed a role for this polymorphism in an increased risk of epilepsy and the development of drug resistance [6] . However, several studies failed to find any influence of this polymorphism on the drug-resistant phenotype in patients with epilepsy [9, 15, 17, 18] . These differences between the studies may be due to many factors, including genetic differences, sample size, age distribution of the cohort, environmental factors, and physician bias.
In our study, we focused on the role of the SCN1A c.3184A > G/p. Thr1067Ala polymorphism in the risk of epilepsy and the treatment response. This polymorphism results in the substitution of the amino acid threonine by alanine at a highly consensus conserved site in the coding region of the SCN1A gene, and thus it possibly affects the function of the inactivation gate in the cytosol regulating efflux and influx of sodium ions [9] . However, this polymorphism may be in linkage disequilibrium with some other genetic variants of the same gene that imparts an increased risk of epilepsy [9] .
Some, but not all studies, have already shown an association of another SCN1A polymorphism, rs3812718 (IVS5N + 5 G > A), with epilepsy susceptibility and its drug responsiveness [19] . This polymorphism leads to a splicing site mutation, which causes a simultaneous substitution of three amino acids. A significant association between the rs3812718 AA genotype and epilepsy susceptibility, as well as CBZ resistance, was identified in Japanese patients [19] . On the other hand, in epilepsy patients from North India, the rs3812718 polymorphism was associated with susceptibility to the disease, but not with drug responsiveness [20] . In European Caucasian epilepsy patients from Spain, this polymorphism was not associated with drug-resistant epilepsy either [18] .
Additionally, there was no correlation between another SCN1A genotype (c.603-91G > A or rs3812718) and dosages of carbamazepine or oxcarbazepine in Italian patients [21] . In Austrian patients there was also no significant difference in the average carbamazepine doses between the genotype groups of the polymorphism IVS5N + 5 G > A or rs3812718 of the gene SCN1A [22] .
As different polymorphisms were analyzed in the abovementioned studies, it is difficult to compare the results and draw general conclusions about their importance. Nevertheless, it is possible that there is a common influence on the treatment response, which, if known, could enable the choice of the appropriate drug and thus personalized treatment.
The role of SCN1A polymorphisms in the risk of epilepsy and the treatment response requires further studies in larger cohorts of clinically well-characterized patients, stratified by age and aetiology of epilepsy [18] .
Our study had several limitations: the study population included patients with different types of epilepsies and aetiologies, and more than seven different antiepileptic drugs were used as the first AED. Due to the relatively small sample size, making correlations between the specific subgroups was not feasible, and the role of the c.3184A > G/p.Thr1067Ala polymorphism in the risk and treatment efficacy stratified by the aetiology of epilepsy and by different mechanisms of antiepileptic drugs, could not be explored. On the other hand, even some studies with a larger number of patients were not able to demonstrate any significant correlation, despite focusing on patients with focal epilepsies and monotherapy with CBZ/OXC or VPA [7] . Therefore, we decided to study all our patients as one group, although they were heterogeneous according to aetiology and overall drug responsiveness.
Our study was not biased by genetic heterogeneity since all patients included in the study come from a small and ethnically homogeneous population [23] , and the treatment and follow-ups were centralized as all patients were treated and followed up in the same tertiary centre.
Further studies should include other parameters involved in antiepileptic treatment to better evaluate the role of the genetic variations in the treatment response and support the possibility of personalized drug treatment.
Conclusions
The SCN1A c.3184A > G/p.Thr1067Ala polymorphism is associated with a tendency towards a lower risk of epilepsy and with a significantly higher remission rate in Slovenian children and adolescents with epilepsy. Further studies on larger groups of patients stratified for the aetiology of epilepsy and antiepileptic treatment are needed to elucidate the role of SCN1A c.3184A > G/p. Thr1067Ala. The data obtained could support personalized drug treatment in epilepsy patients in clinical practice.
